The company currently holds 29.06 B in liabilities with Debt to Equity (D/E)
ratio of 133.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio
of 2.94 suggesting that it is liquid enough
and is able to pay its financial obligations when they are due.